**Drugs that prolong the QT interval + Other drugs that prolong the QT interval**

The concurrent use of more than one drug that prolongs the QT interval increases the risk of torsade de pointes, which might lead to life-threatening ventricular arrhythmias. The risk varies with different combinations of drugs that prolong the QT interval, and with the presence of other risk factors for this effect.

**Clinical evidence, mechanism, importance and management**

If the QT interval on the ECG becomes excessively prolonged, ventricular arrhythmias can develop, in particular a type of polymorphic tachycardia known as torsade de pointes. On the ECG this arrhythmia can appear as an intermittent series of rapid spikes during which the heart fails to pump effectively, the blood pressure falls and the patient will feel dizzy and might lose consciousness. Usually the condition is self-limiting but it might progress and degenerate into ventricular fibrillation, which can cause sudden death.

There are a number of reasons why QT interval prolongation can occur. These include:

increasing age

female sex

congenital long QT syndrome

cardiac disease

thyroid disease

some metabolic disturbances (hypocalcaemia, hypokalaemia, hypomagnesaemia)

Another important cause is the use of various QT-prolonging drugs including some antiarrhythmics, antipsychotics, antihistamines, antimalarials and others. [1,2](https://www.medicinescomplete.com/mc/stockley/current/x04-2399.htm?q=qt%20prolongation&t=search&ss=text&tot=174&p=2#x04-2399-1) These drugs all appear to cause this effect by blocking the rapid component of the delayed rectifier (repolarisation) potassium channel.

At what degree of prolongation of corrected QT (QTc) interval torsade de pointes is likely to develop is uncertain. However, a QTc interval exceeding 500 milliseconds is generally considered of particular concern, but this is not an exact figure. In addition, there is uncertainty about what constitutes an important change in QTc interval from baseline, although, in general, increases of 30 to 60 milliseconds should raise concern, and increases of over 60 milliseconds raise clear concerns about the potential for arrhythmias. Because of these uncertainties, historically, many drug manufacturers and regulatory agencies contraindicated the concurrent use of drugs known to prolong the QT interval, and a ‘blanket’ warning was often issued because the QT prolonging effects of the drugs are expected to be additive. However, regulatory guidance developed in 2005, [3,4](https://www.medicinescomplete.com/mc/stockley/current/x04-2399.htm?q=qt%20prolongation&t=search&ss=text&tot=174&p=2#x04-2399-3) provides recommendations for the assessment of risk of a non-antiarrhythmic drug, and in particular outlines the criteria for studying these effects, in what is called a ‘Thorough QT/QTc study’ which is considered the definitive study design. One of the key criteria of such studies is that it should include use of a positive control, i.e. a drug known to cause an increase in QTc interval of about 5 milliseconds [moxifloxacin is often used for this purpose]. Further, the guidance states that drugs causing an increase in mean QT/QTc interval of around 5 milliseconds or less do not appear to cause torsade de pointes. Data on drugs causing mean increases of around 5 milliseconds and less than 20 milliseconds are inconclusive, and some drugs causing this have been associated with proarrhythmic risk. Drugs with an increase of more than 20 milliseconds have a substantially increased likelihood of being proarrhythmic. [3,4](https://www.medicinescomplete.com/mc/stockley/current/x04-2399.htm?q=qt%20prolongation&t=search&ss=text&tot=174&p=2#x04-2399-3) The extent of the drug-induced prolongation usually depends on the dose of the drug and the particular drugs in question.

‘[Table 9.2](https://www.medicinescomplete.com/mc/stockley/current/Table9.2.htm)’ is a list of drugs that are known to prolong the QT interval and cause torsade de pointes. Note that this list is not exhaustive of all the drugs that have ever been reported to be associated with QT intervalprolongation and torsade de pointes. For some of the drugs listed, QT prolongation is a fairly frequent effect when the drug is used alone, and it is well accepted that use of these drugs requires careful monitoring (e.g. a number of the antiarrhythmics). For other drugs, QT prolongation is rare, but because of the relatively benign indications for these drugs, the risk-benefit ratio is considered poor, and use of these drugs has been severely restricted or discontinued (e.g. astemizole, terfenadine, cisapride). For others there is less clear evidence of the risk of QT prolongation (e.g. clarithromycin, chlorpromazine). Drugs that have only been associated with isolated cases of torsade de pointes, and drugs that are commonly considered to cause QT prolongation, but for which there does not appear to be any published evidence to support this effect (e.g. **chloroquine**), are not usually included in this table. Specific reports of additive QT-prolonging effects with or without torsade de pointes are covered in individual monographs.

Drugs that do not themselves prolong the QT interval, but potentiate the effect of drugs that do (e.g. by pharmacokinetic mechanisms, lowering serum potassium, or by causing bradycardia) are not included in ‘[Table 9.2](https://www.medicinescomplete.com/mc/stockley/current/Table9.2.htm)’. The interactions of these drugs (e.g. azole antifungals with cisapride, astemizole, or terfenadine, and potassium-depleting diuretics with sotalol) are dealt with in individual monographs. However, note that some drugs, for example the macrolide antibacterials, might cause QT prolongation by dual mechanisms: they appear to have both the intrinsic ability to prolong the QT interval, and they might inhibit the metabolism of drugs that prolong the QT interval. [5](https://www.medicinescomplete.com/mc/stockley/current/x04-2399.htm?q=qt%20prolongation&t=search&ss=text&tot=174&p=2#x04-2399-5)

General references discussing the problems of QT-prolongation are given below. [6-15](https://www.medicinescomplete.com/mc/stockley/current/x04-2399.htm?q=qt%20prolongation&t=search&ss=text&tot=174&p=2#x04-2399-6)

The consensus of opinion is that the concurrent use of drugs that have a high risk of prolonging the QTc interval should be avoided because of the risk of additive effects, leading to the possible development of serious and potentially life-threatening torsade de pointes. However, under certain circumstances (e.g. in the treatment of life-threatening arrhythmias) concurrent use might be unavoidable. In this situation close ECG monitoring, and a careful consideration of other risk factors present is essential. With drugs that have some risk of prolonging the QTc interval, some caution is appropriate, particularly in patients with other risk factors for QTc prolongation.

**Table 9.2**

**Table 9.2 Drugs causing QT prolongation and torsade de pointes**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  | | --- | --- | --- | | **High risk** | **Some risk** | **Risk not categorised** | | Antiarrhythmics, class Ia (ajmaline, cibenzoline, disopyramide, hydroquinidine, procainamide, quinidine)  Antiarrhythmics, class III (amiodarone, azimilide, cibenzoline, dofetilide,† dronedarone, ibutilide,†sotalol†)  Arsenic trioxide (40% of patients had a QTc interval greater than 500 milliseconds)  Artemisinin derivatives (artemisinin, artemether/lumefantrine, artenimol - 5% of patients had an asymptomatic prolongation of QTc intervals by greater than 30 milliseconds, with an actual QTc of greater than 450 milliseconds in males and greater than 470 milliseconds in females)  Halofantrine†  Haloperidol (risk increased in high doses and with intravenous use)  Ketanserin (30% of patients had an increase of greater than 30 milliseconds in a clinical trial)  Mesoridazine†  Pimozide†  Sertindole†  Thioridazine†  Vandetanib (QTcF prolonged by 35 milliseconds, with greater than 60 millisecond increase in QTcF interval in 36% of patients) | Amisulpride  Bedaquiline (QTcF interval prolonged by 15.7 to 23.7 milliseconds)  Bosutinib (QTcF interval greater than 500 milliseconds reported in some patients, with greater than 60-millisecond increase in 0.9% of patients)  Chlorpromazine  Citalopram (dose-dependent increase in QTcF interval of 7.5 to 18.5 milliseconds).  Crizotinib (QTcF interval greater than 500 milliseconds reported in some patients, with greater than 60-millisecond increase in 5% of patients)  Dasatinib (increase in QTcF interval of 7 to 13.4 milliseconds)  Delamanid (QTcF interval increased by 7.6 to 12.1 milliseconds, with greater than 60-millisecond increase in 3% of patients)  Dolasetron\* (increase in QTcF interval of 14.1 milliseconds, larger increases have been seen in overdose; not all studies have found an increase)  Droperidol†  Eribulin (QTcF interval prolonged by 11.4 milliseconds on day 8 of use)  Escitalopram (QTcF interval prolonged by 10.7 milliseconds with 30 mg daily)  Gatifloxacin (increase in QTc interval less than 10 milliseconds)  Iloperidone (12 mg twice daily increased QTc interval by 9 milliseconds; greater increases if metabolism inhibited)  Hydroxyzine  Levomepromazine  Methadone (in doses greater than 100 mg)  Moxifloxacin (increase in QTc interval less than 10 milliseconds)  Nilotinib (QTc interval prolonged by 5 to 15 milliseconds)  Ondansetron\* (dose-related prolongation of QTcF interval of up to 20 milliseconds)  Paliperidone (dose-dependent prolongation of 6.8 to 12.3 milliseconds)  Pasireotide (QTcF interval prolongation that equates to a 17.5 millisecond increase over placebo)  Pazopanib (QT interval of greater than 500 milliseconds in some patients)  Quinine (greater risk with higher doses and intravenous use)  Ranolazine (dose-related QTc interval prolonged by up to 15 milliseconds, or more if metabolism inhibited)  Romidepsin (QTc interval prolongation of 14.4 milliseconds in lymphoma patients)  Saquinavir boosted with ritonavir (QTcS interval increased by 18.9 milliseconds with 1 g/100 mg twice daily)  Sildenafil (QT interval prolonged by 6 milliseconds with 50 mg dose; not all studies have found an increase)  Sorafenib (QTcF interval prolonged by 9 milliseconds)  Sparfloxacin (QTcF interval prolonged by 10 milliseconds in clinical studies)  Sultopride†  Sunitinib (QTcF interval prolonged by 9.6 milliseconds)  Telaprevir (QT interval prolonged by 8 milliseconds)  Tolterodine (QTcF interval prolonged by up to 11.8 milliseconds)  Toremifene (Dose-related effect; QT interval prolonged by 21 to 26 milliseconds with 80 mg dose)  Tricyclics (prolongation of QTc interval greater than 10 milliseconds, most notable risk occurs with clomipramine, risk with other tricyclics largely seems to be in overdose)  Vardenafil (QTcF interval prolonged by 8 milliseconds with 10 mg dose)  Ziprasidone (QTc interval prolonged by about 10 milliseconds with 160 mg dose) | Amifampridine (no data but because of the arrhythmogenic potential of amifampridine other drugs that prolong the QT interval are contraindicated)  Androgen antagonists (abiraterone, bicalutamide, enzalutamide, flutamide, nilutamide - lack of direct evidence but note, low testosterone concentrations are associated with an increase in the QT interval)  Asenapine (QTc interval increased by 2 to 5 milliseconds with 5 to 20 mg daily; nevertheless some advise caution or avoiding other QT prolonging drugs)  Atomoxetine (No significant change in QTc interval from baseline in a study; however because of post-marketing reports of QT interval prolongation, some advise caution with other QT prolonging drugs)  Azithromycin (because of post-marketing reports of QT interval prolongation, some advise caution with other QT prolonging drugs)  Boceprevir (no effect seen in studies; nevertheless UK manufacturer advises caution with other drugs that prolong the QT interval)  Clarithromycin (increase in QTc interval of less than 5 milliseconds but because of rare case reports of torsade de pointes some advise caution with other QT prolonging drugs)  Clozapine (because of post-marketing reports of QT interval prolongation, some advise caution with other drugs that prolong the QT interval)  Erythromycin (greater risk with intravenous use)  Gonadorelin analogues (buserelin, goserelin, histrelin, leuprorelin, triptorelin - lack of direct evidence but note, low testosterone concentrations are associated with an increase in the QT interval)  Gonadorelin antagonists (degarelix - lack of direct evidence but note, low testosterone concentrations are associated with an increase in the QT interval)  Lapatinib (small, dose-dependent prolongation of the QTc interval; magnitude not stated)  Lithium (can increase the QT interval particularly if concentrations increased therefore some advise caution with other QT prolonging drugs)  Lofexidine (because of post-marketing reports of QT interval prolongation, some advise caution with other QT prolonging drugs)  Olanzapine (studies suggest no effect but UK manufacturer advises caution on the basis that other antipsychotics have QT prolonging effects)  Pentamidine (intravenous)  Quetiapine (the available data neither proves nor disproves an effect, therefore some advise caution with other QT prolonging drugs)  Rilpivirine (dose-related QT-prolongation occurs, which is considered unlikely to be clinically relevant at the recommended dose; however, because of the limited information manufacturers advise caution)  Risperidone (lack of direct evidence but note, paliperidone is a metabolite of risperidone and so some advise caution with other QT prolonging drugs)  Sodium stibogluconate (dose-related QT interval prolongation occurs; magnitude not stated, therefore some advise caution with other QT prolonging drugs)  Solifenacin (QTcF interval prolonged by 2 milliseconds with a 10 mg dose; however, because of post-marketing reports of QT interval prolongation, some advise caution with other QT prolonging drugs)  Spiramycin  Sulpiride (because of a few reports of QT interval prolongation, some do not recommend the use of other QT prolonging drugs)  Tacrolimus (because of a few reports of QT interval prolongation, some advise caution with other QT prolonging drugs)  Telavancin (increase in QTc of less than 5 miliseconds, but some advise caution with other QT prolonging drugs)  Telithromycin (minimal effects seen in some studies, but others suggest an effect similar to clarithromycin in small proportion of patients)  Tizanidine (small *in vivo* studies suggest no increase in QT or QTc intervals; however, chronic toxicity studies in *dogs*have resulted in QT prolongation and therefore some advise caution with other QT prolonging drugs)  Trazodone (because of post-marketing reports of QT interval prolongation, some advise caution with other QT prolonging drugs)  Vinflunine (because of a few reports of QT interval prolongation, some do not recommend the use of other QT prolonging drugs)  Zotepine (dose-related QT prolongation said to occur, magnitude not stated)  Zuclopentixol (appears to cause QT prolongation in overdose; because of the known effects of other antipsychotics, some advise caution with other QT prolonging drugs) | | † Indicates drug suspended/restricted in some countries because of this effect \* All 5-HT3-receptor antagonists have been associated with QT-interval prolongation, but the evidence is variable; see [5-HT3-receptor antagonists + Drugs that prolong the QT interval](https://www.medicinescomplete.com/mc/stockley/current/x27-3716.htm). This list is not exhaustive | | | | |

[Top](https://www.medicinescomplete.com/mc/stockley/current/Table9.2.htm)

**References**

1. Zeltzer D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs. Most patients have easily identifiable risk factors. *Medicine* (2003) 82, 282–90.
2. Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Survey. *Eur J Cardiovasc Prev Rehabil* (2005) 12, 363–8.([PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16079644&dopt=Abstract))
3. European Medicines Agency. Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. November 2005. Available at:<http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002879.pdf> (accessed 21/08/15).
4. US Food and Drug Administration. Guidance for Industry: E14 Clinical evaluation of QT/QTc interval prolongationand proarrhythmic potential for non-antiarrhythmic drugs. October 2005. Available at:<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf>(accessed 21/08/15).
5. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. *Clin Infect Dis* (2002) 35, 197–200.([PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12087527&dopt=Abstract))
6. Committee on Safety of Medicines/Medicines Control Agency. Drug-induced prolongation of the QT interval. *Current Problems* (1996) 22, 2.
7. Thomas SHL. Drugs, QT interval abnormalities and ventricular arrhythmias. *Adverse Drug React Toxicol Rev* (1994) 13, 77–102.
8. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. *Eur J Clin Pharmacol* (2000) 56, 1–18.
9. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. *Cardiovasc Res* (2000) 47, 219–33.
10. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. *Prog Cardiovasc Dis* (2001) 43 (Suppl 1): 1–45.
11. Kao LW, Furbee RB. Drug-induced Q–T prolongation. *Med Clin North Am* (2005) 89, 1125–44.
12. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. *Am J Psychiatry* (2001) 158, 1774–82.
13. Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. *Int Clin Psychopharmacol* (2005) 20, 243–51.
14. Committee on Safety of Medicines/Medicines Control Agency. Risk of QT interval prolongation with methadone.*Current Problems* (2006) 31, 6.
15. Committee on Safety of Medicines/Medicines Control Agency. Cardiac arrhythmias associated with antipsychotic drugs. *Current Problems* (2006) 31, 9.

**Reviewed on**19-Jun-2014

**Updated on**30-Sep-2015